Alkermes recently highlighted new data from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, showing clinically meaningful improvements in wakefulness, cognition and fatigue over 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results